<DOC>
	<DOCNO>NCT02948933</DOCNO>
	<brief_summary>The aim study evaluate safety profile Dengvaxia® use real-world immunization set Primary Objective : - To measure incidence select adverse event ( AEs ) serious AEs ( SAEs ) occur period six ( 6 ) month Dengvaxia® dose administration ; - To quantify association Dengvaxia® select AEs SAEs risk window vaccination define , use estimate relative risk - To monitor occurrence frequency hospitalize dengue disease well SAEs lead hospitalization death , include new previously unrecognized SAEs , follow Dengvaxia® administration long term ( 5 year first Dengvaxia® dose administration . Secondary objective : - To identify risk factor hospitalize dengue disease ( severe ) among subject vaccinate Dengvaxia® ; - To describe frequency hospitalize dengue disease and/or SAEs select AEs accord number Dengvaxia® dose and/or interval dos .</brief_summary>
	<brief_title>Cohort Event Monitoring Dengvaxia® , CYD-TDV Dengue Vaccine</brief_title>
	<detailed_description>This prospective multi-national non-interventional study include two component Cohort Event Monitoring ( ) Short-term safety surveillance follow-up 6 month Dengvaxia® dose administration ( ii ) long-term safety surveillance follow-up five year first dose . No vaccine provide part study . Study population identify convenient sample site representative possible vaccination center country . Subjects receive first dose Dengvaxia® participate site recruitment period meet eligibility criterion ask participate . After enrollment , vaccinee contact periodically telephone , e-mail , Short Message Service ( SMS ) follow-up identification outcome Dengvaxia® vaccination status .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<criteria>Subjects receive first dose Dengvaxia® across age group , even vaccination give outside local specific label indication recommendation Informed consent form ( ICF ) Assent form ( AF ) sign date subject ( base local regulation ) , and/or ICF sign date parent ( ) another legal acceptable representative ( independent witness require local regulation ) Subjects telephone contact email address available .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Dengvaxia®</keyword>
</DOC>